Literature DB >> 18282360

Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

Tal Grenader1, Maya Gipps, Anthony Goldberg.   

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We report on a patient with known non-small-cell lung cancer who developed Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18282360     DOI： 10.3816/CLC.2008.n.010

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


  11 in total

1.  Nasal vestibulitis due to targeted therapies in cancer patients.

Authors:  Janelle N Ruiz; Viswanath Reddy Belum; Christine B Boers-Doets; Mini Kamboj; N Esther Babady; Yi-Wei Tang; Tulio A Valdez; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2015-01-22       Impact factor: 3.603

Review 2.  [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].

Authors:  P A Gerber; B A Buhren; S Kürle; B Homey
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

3.  Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).

Authors:  Aminah Jatoi; Shaker R Dakhil; Jeff A Sloan; John W Kugler; Kendrith M Rowland; Paul L Schaefer; Paul J Novotny; Donald B Wender; Howard M Gross; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2010-09-06       Impact factor: 3.603

4.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

Review 5.  Skin toxicities associated with epidermal growth factor receptor inhibitors.

Authors:  Tianhong Li; Roman Perez-Soler
Journal:  Target Oncol       Date:  2009-05-19       Impact factor: 4.493

6.  EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.

Authors:  Rachel L Braden; Milan J Anadkat
Journal:  Support Care Cancer       Date:  2016-04-27       Impact factor: 3.603

Review 7.  Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.

Authors:  L Peuvrel; C Bachmeyer; Z Reguiai; J B Bachet; T André; R J Bensadoun; O Bouché; M Ychou; B Dréno
Journal:  Support Care Cancer       Date:  2012-02-24       Impact factor: 3.359

8.  Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors:  B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677

Review 9.  Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.

Authors:  B Dreno; R J Bensadoun; P Humbert; J Krutmann; T Luger; R Triller; A Rougier; S Seité
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-02-01       Impact factor: 6.166

Review 10.  Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

Authors:  Bernd Tischer; Renate Huber; Matthias Kraemer; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2016-10-07       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.